logo
Book a meeting
XenoPort

Xeno Port

Pharmaceuticals, 3410 Central Expy, Santa Clara, California, 95051, United States, 51-200 Employees

xenoport.com

  • LinkedIn

phone no Phone Number: +14*********

Who is XENOPORT

XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological...

Read More

lock icon Get Full Access
map
  • 3410 Central Expy, Santa Clara, California, 95051, United States Headquarters: 3410 Central Expy, Santa Clara, California, 95051, United States
  • 1999 Date Founded: 1999
  • 51-200 Employees: 51-200
  • dollar-icon Revenue: $25 Million to $50 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Pharmaceuticals

SIC SIC Code: 2834 | NAICS Code: 524210 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from XENOPORT

email-formate-icon
View Email Formats for XenoPort
arrow
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

Join Now

crown-icon Free credits every month

Frequently Asked Questions Regarding XenoPort

Answer: XenoPort's headquarters are located at 3410 Central Expy, Santa Clara, California, 95051, United States

Answer: XenoPort's phone number is +14*********

Answer: XenoPort's official website is https://xenoport.com

Answer: XenoPort's revenue is $25 Million to $50 Million

Answer: XenoPort's SIC: 2834

Answer: XenoPort's NAICS: 524210

Answer: XenoPort has 51-200 employees

Answer: XenoPort is in Pharmaceuticals

Answer: XenoPort contact info: Phone number: +14********* Website: https://xenoport.com

Answer: XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in the United States by XenoPort. Regnite (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in Japan by Astellas Pharma Inc. XenoPort holds all other world-wide rights to gabapentin enacarbil. XenoPort's pipeline of product candidates includes potential treatments for patients with Parkinson's disease, relapsing-remitting multiple sclerosis and psoriasis.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access